“An Apple Pie a Day Does Not Keep the Doctor Away”. Fictional Depictions of Gout in Contemporary Film and Television Rachel Murdoch, MD – University of Auckland
9:00 AM – 11:00 AM ET
Dual-energy CT versus Ultrasound, Alone or in Combination, for the Diagnosis of Gout: A Diagnostic Performance Study Jasvinder Singh, MD, MPH – University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
Dual Energy CT Has Additional Prognostic Value over Clinical Measures in Gout Including Tophi: Best Evidence Synthesis Sara (Sally) K. Stauder, BS – Tulane University
9:00 AM – 11:00 AM ET
A Multicenter, Open-Label, Efficacy and Safety Study of Pegloticase in Patients with Uncontrolled Gout Who Have Undergone Kidney Transplantation: Early Data Report Kenneth Saag, MD, MSc – The University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
Risk of Vertebral Fractures at Lateral Chest Radiographies in Patients with Gout Irene Calabuig, MD – Hospital General Universitario de Alicante
9:00 AM – 11:00 AM ET
Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares Luigi Brunetti, PharmD – Rutgers Ernest Mario School of Pharmacy
9:00 AM – 11:00 AM ET
Changes in Serum Urate, in the First 6-months of Initiation or Change of Urate-Lowering Therapy, Associate with Immediate Health-Related Quality of Life Outcomes in People with Gout Jasvinder Singh, MD, MPH – University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
Nutrient Content of Gout Flare Trigger Foods Tony R. Merriman, PhD – University of Otago
9:00 AM – 11:00 AM ET
The Effects of Dietary Macronutrients on Serum Urate: A Secondary Analysis of the OmniHeart Trial Matthew J. Belanger, MD – Beth Israel Deaconess Medical Center
9:00 AM – 11:00 AM ET
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial Kristian Zobbe, MD – The Parker Institute
9:00 AM – 11:00 AM ET
A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis Philip Robinson, PhD, FRACP, MBChB – University of Queensland
9:00 AM – 11:00 AM ET
Gout and Heart Failure in the US Gurkirpal Singh – ICORE
9:00 AM – 11:00 AM ET
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations Blanka Stiburkova, PhD – Institute of Rheumatology
9:00 AM – 11:00 AM ET
Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1 Megan Leask, PhD – University of Otago
9:00 AM – 11:00 AM ET
Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin Ana Beatriz Vargas-Santos, MD, PhD – Universidade do Estado do Rio de Janeiro
9:00 AM – 11:00 AM ET
Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease Nick A. Sumpter, MS – University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study Lindsay Helget, MD – University of Nebraska Medical Center
9:00 AM – 11:00 AM ET
Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation Nick A. Sumpter, MS – University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction Ana B Arevalo, MD – Mount Sinai St. Luke's-West/ Icahn School of Medicine
9:00 AM – 11:00 AM ET
Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study John Botson, MD, RPh – Orthopedic Physicians Alaska
9:00 AM – 11:00 AM ET
Identification of Intracellular Vacuoles in Synovial Fluid with Calcium Pyrophosphate and Monosodium Urate Crystals María Luisa Peral Garrido – Conselleria de Sanitat Universal i Salut Pública
9:00 AM – 11:00 AM ET
Gout Management Beyond Prescription Writing: The Role of the Pharmacist Emma Dorris, PhD – UNIVERSITY COLLEGE DUBLIN
9:00 AM – 11:00 AM ET
Outcomes and Resource Utilization After Total Knee Arthroplasty in Calcium Pyrophosphate Crystal Deposition Disease Patients: Insights from the National Inpatient Sample Database Mohanad Hadi, MD – Creighton University - Valleywise Health Medical Center
9:00 AM – 11:00 AM ET
Calcium Pyrophosphate Crystal Deposition in Gouty Tophi Ea Hang-Korng – Université Paris, INSERM UMR 1132 BIOSCAR
9:00 AM – 11:00 AM ET
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study Sara K. Tedeschi, MD, MPH – Brigham and Women's Hospital
9:00 AM – 11:00 AM ET
Structured Cardiovascular Assessment in Gout Incorporating Carotid Ultrasound: Analysis of Subsequent Events in the Follow-Up MARIANO ANDRES, PhD – Hospital General Universitario de Alicante-ISABIAL
9:00 AM – 11:00 AM ET
Prospective Study of the Patterns of Joint Involvement for Sequential Gout Flares Natalie McCormick, PhD, MSc – Massachusetts General Hospital
9:00 AM – 11:00 AM ET
Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure Scott Neville, MD – Foot and Ankle Center
9:00 AM – 11:00 AM ET
Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan Hisashi Yamanaka, MD – Sanno Medical Center
9:00 AM – 11:00 AM ET
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers Li-Tain Yeh, PhD – Arthrosi Therapeutics, Inc.
9:00 AM – 11:00 AM ET
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care Joshua Gavin, DO – Virginia Commonwealth University Health System
9:00 AM – 11:00 AM ET
A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study John Botson, MD, RPh – Orthopedic Physicians Alaska
9:00 AM – 11:00 AM ET
Patient Characteristics and Patterns of Urate-lowering Treatments in Older Patients with Incident Gout Kazuki Yoshida, ScD – Brigham and Women's Hospital
9:00 AM – 11:00 AM ET
Epidemiology of Intra-Articular Mineralization on Knee Dual-Energy Computed Tomography: The Multicenter Osteoarthritis Study Tuhina Neogi, MD, PhD, FRCPC – Boston University School of Medicine
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study Michael Toprover, MD – New York University Langone Health
9:00 AM – 11:00 AM ET
Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout Fatima AlDuraibi, MD – University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate Michael E. Weinblatt, MD – Brigham and Women's Hospital
9:00 AM – 11:00 AM ET
The Shrinking Toe: A Sign of Crystal Dissolution During Urate Lowering Treatment of Severe Gouty Arthropathy Thomas Bardin, MD – Hôpital Lariboisiere
9:00 AM – 11:00 AM ET
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout Peter E. Lipsky, MD – AMPEL BioSolutions
9:00 AM – 11:00 AM ET
Renal Evolution During the First Year of Urate-lowering Therapy According to Sonographic Joint Deposition: Data from the Lille-Alicante Inception Cohort Irene Calabuig, MD – Hospital General Universitario de Alicante
9:00 AM – 11:00 AM ET
Musculoskeletal Manifestations in Patients with CD73 Deficiency Cornelia Cudrici, MD – NIH/NHLBI
9:00 AM – 11:00 AM ET
The Discontinuation of Allopurinol in the Inpatient Setting and the Risk of Gout Flare: A Community-Hospital Experience Artem Minalyan, MD – Abington Hospital - Jefferson Health
9:00 AM – 11:00 AM ET
The Changing Epidemiology of Inpatient Gout and Associated Mortality: A 17-year National Study Jasvinder Singh, MD, MPH – University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate in Patients with Gout in a Phase 2a Study Li-Tain Yeh, PhD – Arthrosi Therapeutics, Inc.
9:00 AM – 11:00 AM ET
Denosumab Did Not Improve Computerized Tomography Erosion Scores When Added to Intensive Urate-Lowering Therapy in Gout: Results from a Pilot Study Angelo Gaffo, MD, FACP. – University of Alabama at Birmingham
